IN8bio (INAB) H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference summary

Company overview and expertise

• Focus on developing novel cell therapies using gamma delta T-cells for cancer treatment, leveraging over 30 years of experience in the field.

• DeltEx platform enables expansion, activation, and genetic modification of gamma delta T-cells at scale.

• Mission is to achieve 'Cancer Zero' by safely eliminating all cancer cells and maintaining long-term remission.

• Gamma delta T-cells are highlighted as uniquely capable of targeting tumor heterogeneity and distinguishing healthy from cancerous tissue.

• Multiple studies show higher gamma delta T-cell levels correlate with improved survival outcomes.

Clinical pipeline and trial updates

• INB-100 is the first allogeneic gamma delta T-cell program, with recent data presented at TCT conference.

• INB-300 (CAR T) and INB-500 (iPSC-derived) are preclinical programs seeking partners; a new T-cell engager platform will have data released in spring.

• INB-200 (solid tumor, glioblastoma) and INB-400 (phase two, enrollment suspended) are advancing, with updates expected later this summer.

• INB-100 trial in AML patients shows durable remissions, with no relapses in AML cohort and median follow-up of 20.1 months.

• Compared to real-world controls, trial patients show 100% survival and remission at one year in AML, outpacing national and tertiary center benchmarks.

Scientific rationale and competitive differentiation

• Gamma delta T-cells' polyclonal binding and ability to recognize tumor heterogeneity are emphasized as key advantages over NK and alpha beta T-cells.

• Long-term persistence of allogeneic gamma delta T-cells demonstrated for the first time, with in vivo expansion and survival beyond 365 days.

• Higher levels of gamma delta T-cells post-transplantation linked to over threefold increase in survival, supported by multiple independent studies.

• No observed toxicities such as cytokine release syndrome or neurotoxicity in treated patients.

• Multiple patients remain in remission beyond three years, including those with complex and deadly diseases.